Senti Biosciences (NASDAQ:SNTI – Get Rating) is one of 271 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Senti Biosciences to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Profitability
This table compares Senti Biosciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | -1,457.24% | -48.76% | -35.49% |
| Senti Biosciences Competitors | -4,155.58% | -141.69% | -40.48% |
Analyst Ratings
This is a summary of current ratings and price targets for Senti Biosciences and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 0 | 2 | 2 | 0 | 2.50 |
| Senti Biosciences Competitors | 1085 | 4145 | 11112 | 179 | 2.63 |
Institutional and Insider Ownership
40.8% of Senti Biosciences shares are owned by institutional investors. Comparatively, 46.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Senti Biosciences has a beta of 2.48, meaning that its share price is 148% more volatile than the S&P 500. Comparatively, Senti Biosciences’ peers have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.
Earnings and Valuation
This table compares Senti Biosciences and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Senti Biosciences | $4.29 million | -$58.21 million | -0.47 |
| Senti Biosciences Competitors | $735.87 million | $92.56 million | -2.79 |
Senti Biosciences’ peers have higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Senti Biosciences peers beat Senti Biosciences on 7 of the 13 factors compared.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
